Liver Cirrhosis Market to reach USD 2.15 Billion by 2032

The global liver cirrhosis market size is projected to be worth USD 1.49 billion in 2025. It can scale to a valuation of USD 2.15 billion by 2032. The market is anticipated to exhibit a CAGR of 5.4% during the forecast period (2025-2032).  

The surge in cases of liver disorders and advances in liver transplants are primary drivers of the market. Improvements in healthcare infrastructure and approvals for new drugs for the treatment of liver diseases can bolster the market growth over the forecast period.

However, the high treatment costs can act as a deterrent for the market.

The liver cirrhosis market growth is driven by AI-fueled diagnostic workflows, approval of novel drugs, and focus on metabolic cirrhosis.

The rising prevalence of fatty liver diseases like metabolic dysfunction-associated steatohepatitis (MASH) is anticipated to drive the market growth. Investment in clinical trials for the approval of novel drugs such as semaglutide and pemvidutide by prominent pharmaceutical manufacturers can drive the liver cirrhosis market growth. The acceptance of these drugs by health regulatory authorities can be the first step in achieving treatment for patients with MASH.

Development of novel regenerative treatments for the treatment of late-stage chronic liver diseases can boost the market growth. Ochre Bio and Boehringer Ingelheim decided to collaborate on April 22, 2024, for the discovery and development of new treatments for liver diseases. It will leverage human data and disease models to expedite the development of new drugs.

The use of artificial intelligence (AI) screening tools for faster detection of liver diseases is expected to be a prime opportunity for the liver cirrhosis market. Rising cases of NAFLD is predicted to drive the demand for AI in diagnostic labs. The prevalence of obesity and diabetes is driving the development of NAFLD among patients.

On June 20, 2025, a study by a research group at Osaka Metropolitan University's Graduate School of Medicine developed an AI model for the detection of fatty liver disease using chest X-rays. The model was successful after the study of 6,599 radiographs from 4,414 patients.

The high financial burden for the treatment of liver cirrhosis can present a significant challenge to the market growth. This includes hospitalization expenses, doctor fees, medications, and post-operative care. The financial burden on economically weak nations with limited access to good surgeons and transplantation options can also limit the market growth. However, a higher insurance coverage for liver diseases and financial stimulus packages by governments for patients with liver cirrhosis can bode favorably for the market.

Novo Nordisk’s weight loss drug, Wegovy, can be considered for approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) by the U.S. FDA by the end of 2025.